PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16454695-0	2006	Topotecan is a substrate for multidrug resistance associated protein 4.	Topotecan	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	29-70	
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	Topotecan	92-95	ATP binding cassette subfamily C member 4	Homo sapiens	64-68	
16454695-4	2006	This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4.	Topotecan	247-250	ATP binding cassette subfamily C member 4	Homo sapiens	64-68	
16454695-6	2006	The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods.	Topotecan	34-37	ATP binding cassette subfamily C member 4	Homo sapiens	86-90	
16454695-7	2006	The study demonstrated that MRP4 conferred a 12.03- and 6.86-fold resistance to TPT in the 4- and 48-hr drug-exposure MTT assay, respectively.	Topotecan	80-83	ATP binding cassette subfamily C member 4	Homo sapiens	28-32	
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Topotecan	69-72	ATP binding cassette subfamily C member 4	Homo sapiens	49-53	
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Topotecan	137-140	ATP binding cassette subfamily C member 4	Homo sapiens	109-113	
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	33-36	ATP binding cassette subfamily C member 4	Homo sapiens	66-70	
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	33-36	ATP binding cassette subfamily C member 4	Homo sapiens	168-172	
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	192-195	ATP binding cassette subfamily C member 4	Homo sapiens	66-70	
16454695-9	2006	In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells.	Topotecan	192-195	ATP binding cassette subfamily C member 4	Homo sapiens	168-172	
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Topotecan	166-169	ATP binding cassette subfamily C member 4	Homo sapiens	17-21	
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Topotecan	166-169	ATP binding cassette subfamily C member 4	Homo sapiens	185-189	
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	56-59	ATP binding cassette subfamily C member 4	Homo sapiens	29-33	
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	29-33	
16454695-14	2006	These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4.	Topotecan	64-67	ATP binding cassette subfamily C member 4	Homo sapiens	89-93	
16454695-15	2006	Further studies are needed to explore the role of MRP4 in resistance to, toxicity and pharmacokinetics of TPT in cancer patients.	Topotecan	106-109	ATP binding cassette subfamily C member 4	Homo sapiens	50-54